Neos Therapeutics, Inc. 4
4 · Neos Therapeutics, Inc. · Filed Jul 28, 2015
Insider Transaction Report
Form 4
ROBITAILLE GREGORY J
Director
Transactions
- Conversion
Common Stock
2015-07-28+350→ 47,825 total - Conversion
Series B Preferred Stock
2015-07-28−8,650→ 0 total→ Common Stock (3,604 underlying) - Conversion
Common Stock
2015-07-28+3,604→ 29,314 total - Exercise of In-Money
Preferred Stock Warrant (Right to Buy)
2015-07-28−4,200→ 0 totalExp: 2020-02-23→ Series C Preferred Stock (840 underlying) - Conversion
Series B-1 Preferred Stock
2015-07-28−22,700→ 0 total→ Common Stock (9,458 underlying) - Conversion
Common Stock
2015-07-28+9,458→ 38,772 total - Conversion
Series C Preferred Stock
2015-07-28−840→ 0 total→ Common Stock (350 underlying) - Conversion
Common Stock
2015-07-28+8,703→ 47,475 total - Conversion
Series C Preferred Stock
2015-07-28−20,890→ 0 total→ Common Stock (8,703 underlying)
Footnotes (2)
- [F1]Each share of the Issuer's Series B preferred stock, Series B-1 preferred stock and Series C preferred stock was automatically converted on a 2.4-for-1 basis into common stock immediately prior to the closing of the Issuer's initial public offering. The shares of Series B preferred stock, Series B-1 preferred stock and Series C preferred stock had no expiration date.
- [F2]The preferred stock warrant was automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision pursuant to which the holder received a net number of shares of Series C preferred stock based on the fair market value of such stock at the time of exercise, after deducting the aggregate exercise price (the "Cashless Exercise Provision"). The shares of Series C preferred stock have no expiration date.